$AAPL

Here are Wednesday's biggest analyst calls: Nvidia, SpaceX, Apple, Tesla, Target, Amazon, Microsoft & more

Analysts made several calls: UBS kept Apple neutral citing stable iPhone wait times. Wells Fargo upgraded Pinnacle Financial and downgraded Ally Financial. Deutsche Bank initiated FormFactor as buy. William Blair initiated CoreWeave and Nebius Group as outperform. Bank of America reiterated Nvidia, Intel, Marvell, Micron, and Lam Research as buy. Citi initiated Nuvation Bio as buy and downgraded Moderna to sell. HSBC upgraded Target to buy. Morgan Stanley reiterated Tesla as equal weight.

Original reporting
Published Sep 30, 2026, 12:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 12:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here are Wednesday's biggest analyst calls: Nvidia, SpaceX, Apple, Tesla, Target, Amazon, Microsoft & more — source image
Decision brief

The 30-second read

$AAPLNeutralMed
01

Why it matters

Collective analyst sentiment can influence short‑term price moves, especially for small‑cap names.

02

Market read

The roundup offers fresh analyst viewpoints, creating actionable signals for traders on the listed tickers.

03

What to watch

Potential earnings misses or macro headwinds could reverse sentiment.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst house calls summarizing upgrades, downgrades, and initiations across multiple sectors.

Company-level read

Ticker impact

$AAPLNeutralHigh confidence
Context

UBS reiterates Apple as neutral based on unchanged iPhone wait times.

Expected impact

likely modest downside as market prices in neutral stance

Evidence & confidence

Analyst maintains neutral view; no new catalyst beyond supply data.

$ALLYBearishMedium confidence
Context

Wells Fargo downgrades Ally Financial to equal weight from overweight.

Expected impact

likely pressure on the stock

Evidence & confidence

Analyst cites NIM pressure and credit backdrop.

$CRWVBullishHigh confidence
Context

William Blair initiates CoreWeave as outperform.

Expected impact

upside expected as investors price growth

Evidence & confidence

Backlog of $130 bn and Q2 revenue guidance.

$GOBullishMedium confidence
Context

Bank of America upgrades Grocery Outlet Holdings to buy from neutral.

Expected impact

likely upside

Evidence & confidence

Attractive risk/reward and EBITDA multiple.

$AMZNBullishMedium confidence
Context

Rosenblatt reiterates Amazon as buy, raising price target to $360.

Expected impact

upside potential

Evidence & confidence

Analyst downplays disruption risk.

$MRNABearishMedium confidence
Context

Citi downgrades Moderna to sell from neutral.

Expected impact

downward pressure

Evidence & confidence

Aggressive sales assumptions deemed unrealistic.

$TGTBullishMedium confidence
Context

HSBC upgrades Target to buy from hold, raising target to $190.

Expected impact

potential upside

Evidence & confidence

Shares seen as cheap with earnings upside.

$TSLANeutralHigh confidence
Context

Morgan Stanley reiterates Tesla as equal weight ahead of delivery report.

Expected impact

limited move expected

Evidence & confidence

Forecasted delivery decline noted.

Market effects

Broad analyst upgrades may lift tech and financial sector sentiment.

US market likely sees modest buying pressure across listed names.

Limited to US‑listed equities; no global macro effect.

Counterpoint

Some upgrades may be premature given broader market volatility.

Key entities

  • UBS

    Provides neutral rating on Apple.

  • Wells Fargo

    Issues upgrades/downgrades on financial stocks.

Related articles

$MRNAHigh

ESMO26: Moderna, MSD reveal cancer jab data early after leak

Moderna and MSD (Merck & Co) released early data for their melanoma vaccine, INTerpath-001, showing a 42% reduction in recurrence or death risk when combined with Keytruda. The study met expectations, with 82.2% recurrence-free survival at 24 months. Shares fell after a data leak but partially recovered. ESMO is investigating the breach. Analysts suggest potential billion-dollar sales if approved.

$MRNAHighAI 8/10

Moderna Sinks 17.6% Despite Melanoma Win

Moderna (MRNA) shares dropped 17.6% after early data leak from its melanoma vaccine trial with Merck. The vaccine, combined with Keytruda, reduced recurrence or death risk by 42%. Despite positive results, shares fell due to high expectations. UBS and BMO analysts noted strong data but acknowledged inflated expectations. Volume reached 49.9m shares.

$TSLAHighAI 8/10

Tesla's Automotive Revenue Fell 3%, and Energy Generation and Storage Tumbled 16%. Should Investors Still View Tesla as a Car Company?

Tesla (TSLA) reported a 0.2% revenue decline to $28B in Q2, with automotive revenue down 3% and energy storage down 16%. CEO Elon Musk emphasized future growth from Optimus robot and full self-driving tech, aiming for 20,000 Optimus units weekly by 2027. Despite flat sales, TSLA's stock has risen, trading at a P/E of 200. Analysts question if Tesla can justify its valuation without significant growth in new ventures.